El-Fattah Mohamed Abd, Aboelmagd Mohamed, Elhamouly Mohammed
Department of Internal Medicine, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Department of Internal Medicine, Division of Endemic and Infectious Diseases, Faculty of Medicine, Suez Canal University , Ismailia, Egypt.
United European Gastroenterol J. 2017 Mar;5(2):227-235. doi: 10.1177/2050640616659024. Epub 2016 Jul 9.
To determine the survival outcome and prognostic factors of hepatocellular carcinoma (HCC) survival in patients who underwent radiofrequency ablation (RFA).
The Surveillance, Epidemiology and End Results (SEER) database was queried: There were 2588 HCC patients from 2004 to 2012 who underwent RFA. The Kaplan-Meier curves and the multivariate Cox regression analysis were used to assess the prognostic factors.
With a median follow-up of 20 months, the 1-, 3- and 5-year overall survival (OS) rates were: 83%, 51% and 33%. Patients with a tumor size ≤5 cm in diameter had a better 5-year OS, as compared to patients with a tumor size >5 cm. The 5-year OS was significantly higher among patients with a normal level of alpha-fetoprotein (AFP), compared with those having elevated AFP. In an adjusted multivariate Cox regression analysis, those with ≥60 years of age (HR: 1.19; 95% CI 1.05-1.36), non-Asian race (HR: 1.53; 95% CI 1.30-1.81), tumor size >5 cm (HR: 1.43; 95% CI 1.24-1.65), elevated AFP (HR: 1.42; 95% CI 1.22-1.64), American Joint Committee on Cancer (AJCC) stages II-III (HR: 1.30; 95% CI 1.14-1.48) and the year of diagnosis from 2004-2007 (HR: 1.22; 95% CI 1.07-1.40) were significantly associated with a poor prognosis.
Age, race, tumor size, AFP level, AJCC stage and year of diagnosis were prognostic factors for OS in HCC patients who underwent RFA.
确定接受射频消融（RFA）治疗的肝细胞癌（HCC）患者的生存结局及预后因素。
查询监测、流行病学与最终结果（SEER）数据库：2004年至2012年期间有2588例接受RFA治疗的HCC患者。采用Kaplan-Meier曲线和多因素Cox回归分析评估预后因素。
中位随访时间为20个月，1年、3年和5年总生存率（OS）分别为：83%、51%和33%。与肿瘤直径>5 cm的患者相比，肿瘤直径≤5 cm的患者5年OS更好。甲胎蛋白（AFP）水平正常的患者5年OS显著高于AFP升高的患者。在多因素Cox回归分析中，年龄≥60岁（HR：1.19；95%CI 1.05-1.36）、非亚洲种族（HR：1.53；95%CI 1.30-1.81）、肿瘤直径>5 cm（HR：1.43；95%CI 1.24-1.65）、AFP升高（HR：1.42；95%CI 1.22-1.64）、美国癌症联合委员会（AJCC）II-III期（HR：1.30；95%CI 1.14-1.48）以及2004-2007年诊断的患者（HR：1.22；95%CI 1.07-1.40）与预后不良显著相关。
年龄、种族、肿瘤大小、AFP水平、AJCC分期和诊断年份是接受RFA治疗的HCC患者OS的预后因素。
